Hims & Hers is growing internationally and strengthening its healthcare platform beyond longevity therapies, supported by a $400 million JPMorgan receivables facility that enhances financial flexibility for GLP-1 expansion without dilutive equity financing. The recent $1.15 billion acquisition of Eucalyptus adds 850,000 customers and about $450 million in annual recurring revenue across eight international markets. Despite FDA staff challenges on compounded peptides, Hims & Hers trades at a low forward valuation with expected strong revenue growth in 2026 and 2027. Risks include regulatory uncertainty, convertible note dilution, integration of Eucalyptus, and high market expectations.
Berger Montague PC is investigating Hims & Hers Health, Inc. for potential breaches of fiduciary duties, focusing on allegations that the company improperly shared private user health data with advertisers, engaged in deceptive billing practices, and...
The Federal Trade Commission filed a lawsuit against Hims & Hers Health, Inc. on July 29, 2026, accusing the company of sharing customers' sensitive medical information with third-party advertisers like Snap and Meta Platforms. This alleged deceptive...
Hims & Hers Health, Inc. is under investigation after the Federal Trade Commission sued the company for allegedly sharing customers' medical data with third-party advertisers like Snap and Meta Platforms. The lawsuit accuses Hims & Hers of deceptive ...
Hims & Hers Health, Inc. is under investigation after the FTC sued the company for allegedly sharing customers' medical data with third-party advertisers like Meta Platforms. The lawsuit accuses Hims & Hers of deceptive and unlawful privacy practices...
The Federal Trade Commission (FTC) filed a lawsuit against Hims & Hers Health, Inc. on July 29, 2026, accusing the company of illegally sharing customers' medical information with third-party advertisers like Snap and Meta Platforms. This lawsuit all...
